Comparative Study of Rosuvastatin/Ezetimib 20/10 mg and Atovastatin/Ezetimib 40/10 mg (TOLERANT Trial)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 200 participants.
Also called NCT05910476
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT05910476
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05910476. Randomized; no masking; primary purpose treatment. Start 2023-05-03 (actual); primary completion 2026-09-22 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparative Study of Rosuvastatin/Ezetimib 20/10 mg and Atovastatin/Ezetimib 40/10 mg (TOLERANT Trial)
- Condition
- Coronary Artery Disease
- Condition
- Dyslipidemias
- Intervention (Drug)
- a high dose of statin/ezetimib
- Lead sponsor
- Yonsei University
- Collaborator
- dotter
Record details
- Record id
cardio:ct-nct05910476- Content hash
653efbbe7356f192d08b76711e873055c01e0f159ba008c74a5cdefc798c6f95